Hrebícek J, Skottová N, Chmela Z, Hrbková M
Ustav patologické fyziologie, LF UP, Olomouc.
Cas Lek Cesk. 1995 Mar 8;134(5):141-4.
Duolip forte (ethophyllinclofibrate) is a lipid lowering drug, the effect of which was not yet adequately verified in our conditions, namely from the point of its effect on various types of hyperlipoproteinaemias.
The therapy was applied on 45 patients with combined hyperlipidaemia, 25 men and 20 women, mean age 53.8 years (age range 41-65). About one half of patients were treated for hypertension, almost one quart of them manifested ischemic heart disease, 13% had a history of myocardial infarction and the same percentage suffered from associated diabetes type 2. Duolip forte was administered perorally in a dose of 500 mg once daily for 12-16 weeks to the patients who had complied with the prescribed diet (weight loss, improvement of lipid levels) during three-month preliminary period, but did not reach desirable parameters. After the therapy, the whole group studied manifested a significant decrease of total cholesterol (-10.8%), LDL-cholesterol (-13%), triglycerides (-40.8%) and free fatty acids (-20.6%), while the increase of HDL-cholesterol and its fractions was not significant. In hyperlipoproteinaemias of IIa type (n = 15), only a significant decrease of LDL-cholesterol appeared, in hyperlipoproteinaemias of IIb type (n = 15), a significant decrease was evidenced only in triglycerides (-33.9%). In hyperlipoproteineaemias of IV type (n = 15), a significant decrease was observed in triglycerides (-50.3%), while HDL-2 cholesterol values increased (+32.3%). A slight decrease of uric acid level and of body mass index observed in all groups was statistically not significant, as well as a slight increase of glycaemia and changes of serum transaminases. No unwanted side effects of Duolip were found.
Ethophyllinclofibrate has proved as effective namely at hypertriglyceridemic primary hyperlipidaemias. Besides decreasing triglycerides, it increases significantly HDL-2 cholesterol. A convenient dosage, small lithogenic effect and minimum of side effects make it a drug of choice for some groups of elderly high-risk patients.
多利平强力片（益多酯）是一种降脂药物，但其在我们的环境中的效果，即从其对各种类型的高脂蛋白血症的影响来看，尚未得到充分验证。
对45例混合性高脂血症患者进行了治疗，其中男性25例，女性20例，平均年龄53.8岁（年龄范围41 - 65岁）。约一半患者患有高血压，近四分之一患者患有缺血性心脏病，13%有心肌梗死病史，相同比例的患者患有2型糖尿病。对于在三个月的预备期内遵守规定饮食（体重减轻、血脂水平改善）但未达到理想参数的患者，口服多利平强力片，剂量为500毫克，每日一次，持续12 - 16周。治疗后，整个研究组的总胆固醇（-10.8%）、低密度脂蛋白胆固醇（-13%）、甘油三酯（-40.8%）和游离脂肪酸（-20.6%）均显著降低，而高密度脂蛋白胆固醇及其组分的升高不显著。在IIa型高脂蛋白血症（n = 15）中，仅低密度脂蛋白胆固醇显著降低；在IIb型高脂蛋白血症（n = 15）中，仅甘油三酯显著降低（-33.9%）。在IV型高脂蛋白血症（n = 15）中，甘油三酯显著降低（-50.3%），而HDL - 2胆固醇值升高（+32.3%）。所有组中观察到的尿酸水平和体重指数的轻微降低在统计学上不显著，血糖的轻微升高和血清转氨酶的变化也是如此。未发现多利平有不良副作用。
益多酯已被证明对高甘油三酯原发性高脂血症有效。除了降低甘油三酯外，它还能显著升高HDL - 2胆固醇。方便的剂量、较小的致石作用和最少的副作用使其成为一些老年高危患者群体的首选药物。
